Počet záznamů: 1
Antihypertensive and metabolic effects of empagliflozin in Ren-2 transgenic rats, an experimental non-diabetic model of hypertension
- 1.
SYSNO ASEP 0547427 Druh ASEP J - Článek v odborném periodiku Zařazení RIV J - Článek v odborném periodiku Poddruh J Článek ve WOS Název Antihypertensive and metabolic effects of empagliflozin in Ren-2 transgenic rats, an experimental non-diabetic model of hypertension Tvůrce(i) Hojná, Silvie (FGU-C) RID, ORCID
Rauchová, Hana (FGU-C) RID, ORCID
Malínská, H. (CZ)
Marková, I. (CZ)
Hüttl, M. (CZ)
Papoušek, František (FGU-C)
Behuliak, Michal (FGU-C) RID, ORCID
Miklánková, D. (CZ)
Vaňourková, Z. (CZ)
Neckář, Jan (FGU-C) RID, ORCID
Kadlecová, Michaela (FGU-C) RID
Kujal, P. (CZ)
Zicha, Josef (FGU-C) RID, ORCID, SAI
Vaněčková, Ivana (FGU-C) RID, ORCIDČíslo článku 112246 Zdroj.dok. Biomedicine & Pharmacotherapy. - : Elsevier - ISSN 0753-3322
Roč. 144, Dec (2021)Poč.str. 11 s. Jazyk dok. eng - angličtina Země vyd. FR - Francie Klíč. slova SGLT-2 inhibitor ; cardiac ; renal and metabolic parameters Vědní obor RIV ED - Fyziologie Obor OECD Physiology (including cytology) CEP GA19-06199S GA ČR - Grantová agentura ČR Způsob publikování Open access Institucionální podpora FGU-C - RVO:67985823 UT WOS 000704894600003 EID SCOPUS 85117067903 DOI 10.1016/j.biopha.2021.112246 Anotace The new antidiabetic drugs, gliflozins, inhibit sodium-glucose transporter-2 in renal proximal tubules promoting glucose and sodium excretion. This leads not only to a significant improvement of glucose control but also to the reduction of blood pressure and body weight in both diabetic patients and experimental models. We examined whether these beneficial effects can also be achieved in a non-diabetic hypertensive model, namely in Ren-2 transgenic rats (TGR). Adult 6-month-old hypertensive TGR and their normotensive controls (Hannover Sprague-Dawley rats), were either untreated or treated with empagliflozin (10 mg/kg/day) for two months. Telemetric blood pressure monitoring, renal parameters as well as cardiac function via echocardiography were analyzed during the experiment. At the end of the study, the contribution of major vasoactive systems to blood pressure maintenance was studied. Metabolic parameters and markers of oxidative stress and inflammation were also analyzed. Empagliflozin had no effect on plasma glucose level but partially reduced blood pressure in TGR. Although food consumption was substantially higher in empagliflozin-treated TGR compared to the untreated animals, their body weight and the amount of epididymal and perirenal fat was decreased. Empagliflozin had no effect on proteinuria, but it decreased plasma urea, attenuated renal oxidative stress and temporarily increased urinary urea excretion. Several metabolic (hepatic triglycerides, non-esterified fatty acids, insulin) and inflammatory (TNF-alpha, leptin) parameters were also improved by empagliflozin treatment. By contrast, echocardiography did not reveal any effect of empagliflozin on cardiac function. In conclusion, empagliflozin exerted beneficial antihypertensive, anti-inflammatory and metabolic effects also in a non-diabetic hypertensive model. Pracoviště Fyziologický ústav Kontakt Lucie Trajhanová, lucie.trajhanova@fgu.cas.cz, Tel.: 241 062 400 Rok sběru 2022 Elektronická adresa https://doi.org/10.1016/j.biopha.2021.112246
Počet záznamů: 1